Synthesis and biological evaluation of GPR40/FFAR1 agonists containing 3,5-dimethylisoxazole

European Journal of Medicinal Chemistry

Volumn 116, Issue , 2016, Pages 46-58

  Yang, Lingyun ^a   Zhang, Jian ^a   Si, Lianghui ^a   Han, Li ^a   Zhang, Bo ^a   Ma, Hui ^a   Xing, Junhao ^a   Zhao, Leilei ^a   Zhou, Jinpei ^a   Zhang, Huibin ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

3,5 Dimethylisoxazole; Diabetes; GPR40 agonist; Oral glucose tolerance test

Indexed keywords

3 (2 FLUORO 4 HYDROXYPHENYL)ACRYLIC ACID; 3 (2 FLUORO 4 HYDROXYPHENYL)PROPANOATE; 3 (2 FLUORO 4 HYDROXYPHENYL)PROPANOIC ACID; 3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 HYDROXYBENZALDEHYDE; 3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 METHOXYBENZALDEHYDE; 3 (3,5 DIMETHYLISOXAZOL 4 YL)BENZALDEHYDE; 3 BROMO 5 (1,3 DIOXOLAN 2 YL)ANILINE; 3 BROMO 5 HYDROXYBENZALDEHYDE; 3 BROMO 5 NITROBENZALDEHYDE; 3 [4 [[2 CHLORO 5 (3,5 DIMETHYLISOXAZOL 4 YL)BENZYL]OXY] 2 FLUOROPHENYL]PROPANOIC ACID; 3 [4 [[3 (3,5 DIMETHYLISOXAZOL 4 YL) 2 FLUOROBENZYL]OXY] 2 FLUOROPHENYL]PROPANOIC ACID; 3 [4 [[3 (3,5 DIMETHYLISOXAZOL 4 YL) 4 FLUOROBENZYL]OXY] 2 FLUOROPHENYL]PROPANOIC ACID; 3 [4 [[3 (3,5 DIMETHYLISOXAZOL 4 YL) 4 METHOXYBENZYL]OXY] 2 FLUOROPHENYL]PROPANOIC ACID; 3 [4 [[3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 (TRIFLUOROMETHYL)BENZYL]OXY] 2 FLUOROPHENYL]PROPANOIC ACID; 3 [4 [[3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 FLUOROBENZYL]OXY] 2 FLUOROPHENYL]PROPANOIC ACID; 3 [4 [[3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 ISOPROPOXYBENZYL]OXY] 2 FLUOROPHENYL]PROPANOIC ACID; 3 [4 [[3 (3,5 DIMETHYLISOXAZOL 4 YL) 5 METHYLBENZYL]OXY] 2 FLUOROPHENYL]PROPANOIC ACID; 3 [4 [[3 (3,5 DIMETHYLISOXAZOL 4 YL)BENZYL]OXY] 2 FLUOROPHENYL]PROPANOATE; 3 [4 [[3 (3,5 DIMETHYLISOXAZOL 4 YL)BENZYL]OXY] 2 FLUOROPHENYL]PROPANOIC ACID; 3 [4 [[3 CHLORO 5 (3,5 DIMETHYLISOXAZOL 4 YL)BENZYL]OXY] 2 FLUOROPHENYL]PROPANOIC ACID; 3 [4 [[4 CHLORO 3 (3,5 DIMETHYLISOXAZOL 4 YL)BENZYL]OXY] 2 FLUOROPHENYL]PROPANOIC ACID; 3 [4 [[5 (3,5 DIMETHYLISOXAZOL 4 YL) 2 FLUOROBENZYL]OXY] 2 FLUOROPHENYL)PROPANOIC ACID; 3 [4 [[5 (3,5 DIMETHYLISOXAZOL 4 YL) 2 METHOXYBENZYL]OXY] 2 FLUOROPHENYL]PROPANOIC ACID; 4 [3 (CHLOROMETHYL)PHENYL] 3,5 DIMETHYLISOXAZOLE; ANTIDIABETIC AGENT; FASIGLIFAM; G PROTEIN COUPLED RECEPTOR 40 AGONIST; METHYL 3 [4 [[3 (3,5 DIMETHYLISOXAZOL 4 YL)BENZYL]OXY] 2 FLUOROPHENYL]PROPANO; UNCLASSIFIED DRUG; UNINDEXED DRUG; [3 (3,5 DIMETHYLISOXAZOL 4 YL)PHENYL]METHANOL; G PROTEIN COUPLED RECEPTOR; GPR40 PROTEIN, MOUSE; OXAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SCREENING; DRUG SYNTHESIS; EC50; FEMALE; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DOCKING; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; AGONISTS; ANIMAL; CHEMISTRY; METABOLISM; PROTEIN CONFORMATION; RAT; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; CHEMISTRY TECHNIQUES, SYNTHETIC; HYPOGLYCEMIC AGENTS; MALE; MICE; MOLECULAR DOCKING SIMULATION; OXAZOLES; PROTEIN CONFORMATION; RATS; RECEPTORS, G-PROTEIN-COUPLED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84962429381     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2016.03.054     Document Type: Article

References (32)

1. B.L. Wajchenberg β-cell failure in diabetes and preservation by clinical treatment Endocr. Rev. 28 2007 187 218
2. M.E. Doyle, and J.M. Egan Pharmacological agents that directly modulate insulin secretion Pharmacol. Rev. 55 2003 105 131
3. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 2006 1696 1705
4. H. Bays Sodium glucose Co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus Diabetes Ther. 4 2013 195 220
5. Y. Itoh, Y. Kawamata, M. Harada, M. Kobayashi, R. Fujii, S. Fukusumi, K. Ogi, M. Hosoya, Y. Tanaka, H. Uejima, H. Tanaka, M. Maruyama, R. Satoh, S. Okubo, H. Kizawa, H. Komatsu, F. Matsumura, Y. Noguchi, T. Shinohara, S. Hinuma, Y. Fujisawa, and M. Fujino Free fatty acids regulate insulin secretion from pancreatic [beta] cells through GPR40 Nature 422 2003 173 176
6. C.P. Briscoe, M. Tadayyon, J.L. Andrews, W.G. Benson, J.K. Chambers, M.M. Eilert, C. Ellis, N.A. Elshourbagy, A.S. Goetz, D.T. Minnick, P.R. Murdock, H.R. Sauls, U. Shabon, L.D. Spinage, J.C. Strum, P.G. Szekeres, K.B. Tan, J.M. Way, D.M. Ignar, S. Wilson, and A.I. Muir The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids J. Biol. Chem. 278 2003 11303 11311
7. K. Kotarsky, N.E. Nilsson, E. Flodgren, C. Owman, and B. Olde A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs Biochem. Biophys. Res. Commun. 301 2003 406 410
8. S. Edfalk, P. Steneberg, and H. Edlund Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion Diabetes 57 2008 2280 2287
9. M. Prentki, F.M. Matschinsky, and S.R. Madiraju Metabolic signaling in fuel-induced insulin secretion Cell Metab. 18 2013 162 185
10. E. Defossa, and M. Wagner Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus Bioorg. Med. Chem. Lett. 24 2014 2991 3000
11. S.B. Bharate, K.V.S. Nemmani, and R.A. Vishwakarma Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes Expert Opin. Ther. Pat. 19 2009 237 264
12. R. Takano, M. Yoshida, M. Inoue, T. Honda, R. Nakashima, K. Matsumoto, T. Yano, T. Ogata, N. Watanabe, M. Hirouchi, T. Yoneyama, S. Ito, and N. Toda Discovery of DS-1558: a potent and orally bioavailable GPR40 agonist ACS Med. Chem. Lett. 6 2015 266 270
13. S. Sasaki, S. Kitamura, N. Negoro, M. Suzuki, Y. Tsujihata, N. Suzuki, T. Santou, N. Kanzaki, M. Harada, Y. Tanaka, M. Kobayashi, N. Tada, M. Funami, T. Tanaka, Y. Yamamoto, K. Fukatsu, T. Yasuma, and Y. Momose Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists J. Med. Chem. 54 2011 1365 1378
14. S.P. Walsh, A. Severino, C. Zhou, J. He, G.B. Liang, C.P. Tan, J. Cao, G.J. Eiermann, L. Xu, G. Salituro, A.D. Howard, S.G. Mills, and L. Yang 3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists Bioorg. Med. Chem. Lett. 21 2011 3390 3394
15. N. Negoro, S. Sasaki, S. Mikami, M. Ito, Y. Tsujihata, R. Ito, M. Suzuki, K. Takeuchi, N. Suzuki, J. Miyazaki, T. Santou, T. Odani, N. Kanzaki, M. Funami, A. Morohashi, M. Nonaka, S. Matsunaga, T. Yasuma, and Y. Momose Optimization of (2,3-dihydro-1-benzofuran-3-yl)acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucose-dependent insulinotropic agent J. Med. Chem. 55 2012 3960 3974
16. K. Kaku, K. Enya, R. Nakaya, T. Ohira, and R. Matsuno Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial Diabetes Obes. Metab. 17 2015 675 681
17. N. Negoro, S. Sasaki, M. Ito, S. Kitamura, Y. Tsujihata, R. Ito, M. Suzuki, K. Takeuchi, N. Suzuki, J. Miyazaki, T. Santou, T. Odani, N. Kanzaki, M. Funami, T. Tanaka, T. Yasuma, and Y. Momose Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that Act as G Protein-coupled receptor 40/Free fatty acid receptor 1 agonists J. Med. Chem. 55 2012 1538 1552
18. Lead GPR40 agonist bites the dust Nat. Rev. Drug Discov. 13 2014 91
19. D. Ma, B. Tao, S. Warashina, S. Kotani, L. Lu, D.B. Kaplamadzhiev, Y. Mori, A.B. Tonchev, and T. Yamashima Expression of free fatty acid receptor GPR40 in the central nervous system of adult monkeys Neurosci. Res. 58 2007 394 401
20. K. Nakamoto, T. Nishinaka, K. Matsumoto, F. Kasuya, M. Mankura, Y. Koyama, and S. Tokuyama Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system Brain Res. 1432 2012 74 83
21. Z. Ma, D.C. Lin, R. Sharma, J. Liu, L. Zhu, A.R. Li, T. Kohn, Y. Wang, J.J. Liu, M.D. Bartberger, J.C. Medina, R. Zhuang, F. Li, J. Zhang, J. Luo, S. Wong, G.R. Tonn, and J.B. Houze Discovery of the imidazole-derived GPR40 agonist AM-3189 Bioorg. Med. Chem. Lett. 26 2016 15 20
22. T.T. Wager, R.Y. Chandrasekaran, X. Hou, M.D. Troutman, P.R. Verhoest, A. Villalobos, and Y. Will Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes ACS Chem. Neurosci. 1 2010 420 434
23. J. Kelder, P.D. Grootenhuis, D.M. Bayada, L.P. Delbressine, and J.P. Ploemen Polar molecular surface as a dominating determinant for oral absorption and brain penetration of drugs Pharm. Res. 16 1999 1514 1519
24. J.J. Liu, Y. Wang, Z. Ma, M. Schmitt, L. Zhu, S.P. Brown, P.J. Dransfield, Y. Sun, R. Sharma, Q. Guo, R. Zhuang, J. Zhang, J. Luo, G.R. Tonn, S. Wong, G. Swaminath, J.C. Medina, D.C. Lin, and J.B. Houze Optimization of GPR40 agonists for type 2 diabetes ACS Med. Chem. Lett. 5 2014 517 521
25. M.J. Waring Lipophilicity in drug discovery Expert Opin. Drug Discov. 5 2010 235 248
26. X. Du, P.J. Dransfield, D.C. Lin, S. Wong, Y. Wang, Z. Wang, T. Kohn, M. Yu, S.P. Brown, M. Vimolratana, L. Zhu, A.R. Li, Y. Su, X. Jiao, J.J. Liu, G. Swaminath, T. Tran, J. Luo, R. Zhuang, J. Zhang, Q. Guo, F. Li, R. Connors, J.C. Medina, and J.B. Houze Improving the pharmacokinetics of GPR40/FFA1 full agonists ACS Med. Chem. Lett. 5 2014 384 389
27. E. Christiansen, C. Urban, M. Grundmann, M.E. Due-Hansen, E. Hagesaether, J. Schmidt, L. Pardo, S. Ullrich, E. Kostenis, M. Kassack, and T. Ulven Identification of a potent and selective free fatty acid receptor 1 (FFA1/GPR40) agonist with favorable physicochemical and in vitro ADME properties J. Med. Chem. 54 2011 6691 6703
28. R. Takano, M. Yoshida, M. Inoue, T. Honda, R. Nakashima, K. Matsumoto, T. Yano, T. Ogata, N. Watanabe, and N. Toda Discovery of 3-aryl-3-ethoxypropanoic acids as orally active GPR40 agonists Bioorg. Med. Chem. Lett. 24 2014 2949 2953
29. E. Christiansen, S.V.F. Hansen, C. Urban, B.D. Hudson, E.T. Wargent, M. Grundmann, L. Jenkins, M. Zaibi, C.J. Stocker, S. Ullrich, E. Kostenis, M.U. Kassack, G. Milligan, M.A. Cawthorne, and T. Ulven Discovery of TUG-770: a highly potent free fatty acid receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes ACS Med. Chem. Lett. 4 2013 441 445
30. A. Srivastava, J. Yano, Y. Hirozane, G. Kefala, F. Gruswitz, G. Snell, W. Lane, A. Ivetac, K. Aertgeerts, J. Nguyen, A. Jennings, and K. Okada High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875 Nature 513 2014 124 127
31. M.S. Winzell, and B. Ahren The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes Diabetes 53 Suppl. 3 2004 S215 S219
32. J.A. Koehler, L.L. Baggio, B.J. Lamont, S. Ali, and D.J. Drucker Glucagon-like peptide-1 receptor activation modulates pancreatitis-associated gene expression but does not modify the susceptibility to experimental pancreatitis in mice Diabetes 58 2009 2148 2161